Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head …
Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head …
RS Herbst, M Arquette, DM Shin… - Journal of …, 2005 - mdanderson.elsevierpure.com
Purpose: This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …
[引用][C] Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the …
RS HERBST, M ARQUETTE, DM SHIN… - Journal of clinical …, 2005 - pascal-francis.inist.fr
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and
cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck CNRS …
cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck CNRS …
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head …
RS Herbst, M Arquette, DM Shin… - Journal of clinical …, 2005 - pubmed.ncbi.nlm.nih.gov
Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head …
RS Herbst, M Arquette, DM Shin, K Dicke… - Journal of Clinical …, 2005 - europepmc.org
Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …
Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the …
RS Herbst, M Arquette, DM Shin, K Dicke… - Journal of Clinical …, 2005 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> This multicenter phase II study was
undertaken to define the efficacy and safety of cetuximab, an antiepidermal growth factor …
undertaken to define the efficacy and safety of cetuximab, an antiepidermal growth factor …